Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs ASA for secondary prevention in ESUS (RESPECT ESUS)
NCT02239120Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in embolic stroke of undetermined source (ESUS), sponsored by Boehringer Ingelheim. Started Nov 2014; status: completed.
02
Drugs
dabigatran
03
Conditions
embolic stroke of undetermined source (ESUS)
Beyond the preview
Go deeper on NCT02239120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239120.